InvestorTalk Alert: Brent Willis from Voyageur Pharmaceuticals Ltd. to host on Wednesday, June 25, 2025 at 9 AM EST

InvestorNews.com is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Wednesday, June 25th, at 9 AM EST, featuring Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here

Voyageur Pharmaceuticals is a Canadian public company developing barium and iodine-based Active Pharmaceutical Ingredients (APIs) for high-performance, cost-effective imaging contrast agents. The company aims to become the first vertically integrated radiology contrast media producer by sourcing and manufacturing its own raw materials. Voyageur owns 100% of the Frances Creek Project, a rare natural barium sulfate deposit. Voyageur works with GMP-certified pharmaceutical manufacturers in Canada to validate its products, with plans to transition into a high-margin domestic producer. The company is also advancing endo fullerene drug development. Voyageur’s strategy emphasizes quality, cost control, and sustainability—embodied in its vision: “From the Earth to the Bottle.”

In preparation for tomorrow’s InvestorTalk, here are the three most recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:

• June 23, 2025 – Voyageur and Altillion Forge Landmark Alliance to Establish North America’s First Vertically Integrated Iodine Drug Supply Chain — click here
• June 04, 2025 – Voyageur Enters Revenue Stage with First Commercial Sale of Barium Contrast Agents — click here
• May 12, 2025 – Voyageur Pharmaceuticals Announces Appointment of Ethan Mohan as Executive Vice President — click here

Here are 5 key data points from their June 23^rd news release titled, “Voyageur and Altillion Forge Landmark Alliance to Establish North America’s First Vertically Integrated Iodine Drug Supply Chain”:

• Strategic MOU Signed: Voyageur Pharmaceuticals signed a non-binding Memorandum of Understanding (MOU) with Altillion Inc. to develop North America’s first vertically integrated iodine-based drug supply chain.
• Iodine Extraction Technology Goals: The collaboration targets 90% iodine recovery with over 99% purity of I₂ crystalline flake; current benchmark pricing is $70/kg or $70,000/tonne.
• Four-Phase Rollout Plan:
  • Phase 1: Bench-scale validation and licensing.
  • Phase 2: 200-tonne/year pilot API plant.
  • Phase 3: Scale up to 1000 tonnes/year.
  • Phase 4: Full sterile injectable drug manufacturing facility in Texas.
• Domestic Infrastructure Development: Plans include building an iodine extraction facility in Oklahoma and a pharmaceutical manufacturing campus in Texas to support vertical integration.
• Funding and Market Positioning: Voyageur is pursuing non-dilutive funding through government programs and strategic partners, addressing North America’s complete reliance on iodine drug imports amid rising global demand and supply constraints.

For more information on Voyageur Pharmaceuticals Ltd., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.